Social network
Our responsibility

Tools content (print, share, increase/decrease text size):

 

Treating epilepsy

Epilepsy is one of the most common chronic neurological disorders. Worldwide, about 50 million people live with epilepsy, nearly 80% of them in developing countries1.

Patients are stigmatized

Access to care is limited due to inadequate medical resources and medicines, as well as a lack of training of healthcare personnel. Beliefs about epilepsy represent a further obstacle. Some people think it is contagious or a sign of being possessed by spirits and patients are stigmatized. Children with epilepsy may be banned from school and adults may have difficulty finding a job or starting a family. In developing countries, three-fourths of patients do not receive suitable care1.

 

Fighting prejudice and providing suitable care

And yet epilepsy can be successfully treated. In 70% of cases, seizures can be completely controlled with antiepileptic drugs1.

Sanofi is one of first healthcare companies to become actively involved in improving access to care for people with epilepsy in developing countries. In partnership with the Institute of Neuroepidemiology and Tropical Neurology, programs are currently ongoing in Latin America, Africa and Asia to improve access to care, to fight stigmatization, train healthcare professionals and to make medicines more accessible to the most disadvantaged patients through preferential pricing policies.

 

Discover the Access to healthcare program for epilepsy in Laos and Cambodia:

 

For more information:

 

 

References:

  1. WHO, Fact sheet No. 999, February 2016.
 
 

© Sanofi 2004-2017 - All rights reserved - Update: November 28, 2016

  • Site complies with W3C WCAG 2.0 (new window, in english)